Nothing Special   »   [go: up one dir, main page]

BR9913360B1 - proteÍna de uricase recombinante quimÉrica, molÉcula de Ácido nuclÉico isolada e purificada, vetor e cÉlula hospedeira transformada. - Google Patents

proteÍna de uricase recombinante quimÉrica, molÉcula de Ácido nuclÉico isolada e purificada, vetor e cÉlula hospedeira transformada.

Info

Publication number
BR9913360B1
BR9913360B1 BRPI9913360-1B1A BR9913360A BR9913360B1 BR 9913360 B1 BR9913360 B1 BR 9913360B1 BR 9913360 A BR9913360 A BR 9913360A BR 9913360 B1 BR9913360 B1 BR 9913360B1
Authority
BR
Brazil
Prior art keywords
nucleic acid
vector
isolated
host cell
acid molecule
Prior art date
Application number
BRPI9913360-1B1A
Other languages
English (en)
Other versions
BR9913360A (pt
BRPI9913360B8 (pt
Inventor
Michael Hershfield
Susan J Kelly
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR9913360A publication Critical patent/BR9913360A/pt
Publication of BR9913360B1 publication Critical patent/BR9913360B1/pt
Publication of BRPI9913360B8 publication Critical patent/BRPI9913360B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12N9/0048—Uricase (1.7.3.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI9913360A 1998-08-06 1999-08-05 proteína de uricase recombinante quimérica, molécula de ácido nucléico isolada e purificada, vetor e célula hospedeira transformada. BRPI9913360B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9548998P 1998-08-06 1998-08-06
PCT/US1999/017678 WO2000008196A2 (en) 1998-08-06 1999-08-05 Urate oxidase

Publications (3)

Publication Number Publication Date
BR9913360A BR9913360A (pt) 2001-07-03
BR9913360B1 true BR9913360B1 (pt) 2013-09-24
BRPI9913360B8 BRPI9913360B8 (pt) 2021-05-25

Family

ID=22252247

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9913360A BRPI9913360B8 (pt) 1998-08-06 1999-08-05 proteína de uricase recombinante quimérica, molécula de ácido nucléico isolada e purificada, vetor e célula hospedeira transformada.

Country Status (22)

Country Link
US (1) US7056713B1 (pt)
EP (2) EP2277998B1 (pt)
JP (3) JP2002524053A (pt)
KR (1) KR100841634B1 (pt)
CN (2) CN1322243A (pt)
AT (1) ATE483797T1 (pt)
AU (1) AU766421B2 (pt)
BR (1) BRPI9913360B8 (pt)
CA (1) CA2337967C (pt)
CY (1) CY1111001T1 (pt)
CZ (1) CZ304223B6 (pt)
DE (1) DE69942834D1 (pt)
DK (1) DK1100880T3 (pt)
ES (1) ES2352451T3 (pt)
HU (1) HU229774B1 (pt)
IL (3) IL141221A0 (pt)
NZ (1) NZ509633A (pt)
PL (1) PL207369B1 (pt)
PT (1) PT1100880E (pt)
RU (1) RU2290439C2 (pt)
WO (1) WO2000008196A2 (pt)
ZA (1) ZA200100974B (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US20060188971A1 (en) * 1998-08-06 2006-08-24 Duke University Urate oxidase
WO2000007629A2 (en) * 1998-08-06 2000-02-17 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
EP1588716B1 (en) 1998-08-06 2011-02-16 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
AU766421B2 (en) * 1998-08-06 2003-10-16 Duke University Urate oxidase
CN100371439C (zh) * 2003-04-07 2008-02-27 北京双鹭药业股份有限公司 一种重组假丝酵母尿酸氧化酶的制备方法
CN100334207C (zh) * 2004-04-27 2007-08-29 杭州北斗生物技术有限公司 一种黄曲霉尿酸氧化酶的制备方法
LT3321359T (lt) 2005-04-11 2021-05-10 Horizon Pharma Rheumatology Llc Urato oksidazės variantinės formos ir jų panaudojimas
SG161248A1 (en) 2005-04-11 2010-05-27 Savient Pharmaceuticals Inc A variant form of urate oxidase and use thereof
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
AU2011257764B2 (en) * 2005-04-11 2012-04-05 Horizon Therapeutics Usa, Inc. A variant form of urate oxidase and use thereof
PL2013225T3 (pl) 2006-04-12 2015-06-30 Crealta Pharmaceuticals Llc Oczyszczanie białek z zastosowaniem kationowego środka powierzchniowo czynnego
CN101402688B (zh) * 2008-11-18 2011-04-20 中国人民解放军军事医学科学院生物工程研究所 一种融合蛋白及其编码基因与应用
WO2010110464A1 (en) 2009-03-24 2010-09-30 Meito Sangyo Co., Ltd. Improved type milk-clotting protease derived from a microorganism
JP2012531596A (ja) 2009-06-25 2012-12-10 サヴィエント・ファーマシューティカルズ・インコーポレイテッド Ｐｅｇ化ウリカーゼ療法における血清尿酸をモニタリングすることにより注入反応の危険性および抗体媒介性効果消失を予測するための方法およびキット
CN102051348B (zh) * 2009-10-27 2012-10-03 重庆富进生物医药有限公司 人源化重组尿酸酶及其突变体
RU2460793C2 (ru) * 2010-01-15 2012-09-10 Закрытое акционерное общество "Научно-исследовательский институт "Аджиномото-Генетика" (ЗАО АГРИ) Способ получения l-аминокислот с использованием бактерий семейства enterobacteriaceae
WO2011127393A2 (en) 2010-04-08 2011-10-13 Georgia Tech Research Corporation Variants of ancestral uricases and uses thereof
CN102634492B (zh) 2011-02-14 2015-06-10 重庆富进生物医药有限公司 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用
CN102757945B (zh) * 2011-04-28 2015-03-18 杭州俊丰生物工程有限公司 人尿酸氧化酶蛋白及其制备方法和其聚乙二醇结合物
CN102260653B (zh) * 2011-06-30 2013-04-03 荣俊 一种peg化重组猪-人尿酸氧化酶融合蛋白的制备及应用方法
WO2014170916A2 (en) * 2013-04-17 2014-10-23 Council Of Scientific & Industrial Research Novel uricase mutants
CN103834623B (zh) * 2014-02-11 2017-11-07 中国药科大学 具有催化活性的人源尿酸氧化酶
CN104388467A (zh) * 2014-10-27 2015-03-04 李长贵 一种构建自发性高尿酸血症小鼠模型的方法及其用途
EP3294322A4 (en) 2015-05-15 2018-12-12 Medimmune, LLC Improved uricase sequences and methods of treatment
CN106554948B (zh) * 2015-09-29 2019-06-25 上海生物制品研究所有限责任公司 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用
CN108103079B (zh) * 2017-06-20 2021-07-13 北京锦篮基因科技有限公司 一种高尿酸血症的基因治疗药物
CN109554376B (zh) * 2018-11-13 2022-03-22 广西大学 一种碱性尿酸氧化酶及其在检测试剂盒和降低食品中尿酸的应用
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
CN111088268B (zh) * 2019-03-05 2022-08-02 北京锦篮基因科技有限公司 一种高尿酸血症的基因治疗药物
AU2020276510B2 (en) 2019-05-10 2024-08-01 Hangzhou Grand Biologic Pharmaceutical Inc. Polyethylene glycol-modified urate oxidase
CN112646790A (zh) * 2019-10-11 2021-04-13 上海君实生物医药科技股份有限公司 改进的尿酸酶及其用于治疗高尿酸血症的方法
CN111920942A (zh) * 2020-08-24 2020-11-13 深圳前海鹰岗生物科技有限公司 一种用于快速溶解痛风石的聚合物微针及制备方法和应用
CN114438047B (zh) 2020-11-05 2024-11-22 重庆派金生物科技有限公司 制备聚乙二醇修饰的尿酸氧化酶的方法
CN114438048B (zh) 2020-11-05 2024-10-22 重庆派金生物科技有限公司 尿酸氧化酶制剂及其应用
CN112852772A (zh) * 2021-01-19 2021-05-28 中国科学院过程工程研究所 一种基于分子内交联和聚乙二醇修饰的尿酸氧化酶及其制备方法
CN112662640A (zh) * 2021-01-28 2021-04-16 中国药科大学 一种具有催化活性的尿酸氧化酶
CN113244412B (zh) * 2021-06-25 2021-10-26 深圳市瑞吉生物科技有限公司 一种基于mRNA剂型的治疗高尿酸血症或痛风的药物及其制备方法
AU2022340814A1 (en) * 2021-09-01 2024-02-15 Ginkgo Bioworks, Inc. Recombinant cells for treating diseases associated with uric acid and methods of use thereof
WO2024138370A1 (zh) * 2022-12-27 2024-07-04 北京炫景瑞医药科技有限公司 一种治疗高尿酸相关疾病的核酸药物及其制备方法和用途
CN118360300A (zh) * 2023-01-10 2024-07-19 优环(苏州)生物医药科技有限公司 一种表达尿酸氧化酶的环状rna、制备方法及应用
WO2025030053A1 (en) 2023-08-01 2025-02-06 Insmed Incorporated Novel igg proteases and methods of use thereof
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279486C (pt)
US3613231A (en) 1969-07-25 1971-10-19 Paul F Pugh Method for manufacturing high voltage cable systems
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE3126759A1 (de) 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5075216A (en) 1988-09-23 1991-12-24 Cetus Corporation Methods for dna sequencing with thermus aquaticus dna polymerase
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5382518A (en) 1989-07-13 1995-01-17 Sanofi Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5653974A (en) 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
AU6240494A (en) 1993-02-16 1994-09-14 Enzon, Inc. Ribosome inactivating protein compositions having reduced antigenicity
AU7113594A (en) 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
CA2206852A1 (en) 1994-12-07 1996-06-13 Novo Nordisk A/S Polypeptide with reduced allergenicity
JPH09154581A (ja) 1995-12-05 1997-06-17 Asahi Chem Ind Co Ltd ウリカーゼを生産する実質上純粋な微生物
CN1246891A (zh) 1997-02-06 2000-03-08 诺沃挪第克公司 添加和/或除去了连接基团的多肽－聚合物偶联物
AU766421B2 (en) * 1998-08-06 2003-10-16 Duke University Urate oxidase
EP1588716B1 (en) 1998-08-06 2011-02-16 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
WO2000007629A2 (en) 1998-08-06 2000-02-17 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof

Also Published As

Publication number Publication date
ATE483797T1 (de) 2010-10-15
KR100841634B1 (ko) 2008-06-26
IL141221A0 (en) 2002-03-10
JP5721954B2 (ja) 2015-05-20
HUP0103205A3 (en) 2006-01-30
ES2352451T3 (es) 2011-02-18
EP1100880A4 (en) 2002-04-17
EP2277998B1 (en) 2016-04-20
EP2277998A1 (en) 2011-01-26
AU5336599A (en) 2000-02-28
KR20010053633A (ko) 2001-06-25
RU2290439C2 (ru) 2006-12-27
ZA200100974B (en) 2002-06-26
DE69942834D1 (de) 2010-11-18
PL207369B1 (pl) 2010-12-31
CN101280293A (zh) 2008-10-08
IL197339A0 (en) 2011-07-31
HU229774B1 (en) 2014-07-28
CZ304223B6 (cs) 2014-01-15
AU766421B2 (en) 2003-10-16
CZ2001466A3 (cs) 2001-07-11
US7056713B1 (en) 2006-06-06
CA2337967A1 (en) 2000-02-17
HK1153508A1 (en) 2012-03-30
JP2002524053A (ja) 2002-08-06
CY1111001T1 (el) 2015-06-11
PL346222A1 (en) 2002-01-28
HK1125402A1 (en) 2009-08-07
CN1322243A (zh) 2001-11-14
BR9913360A (pt) 2001-07-03
IL141221A (en) 2010-06-16
CN101280293B (zh) 2013-09-11
WO2000008196A2 (en) 2000-02-17
IL197339A (en) 2015-02-26
NZ509633A (en) 2003-04-29
JP2010158244A (ja) 2010-07-22
EP1100880A2 (en) 2001-05-23
PT1100880E (pt) 2011-01-13
DK1100880T3 (da) 2011-01-24
WO2000008196A9 (en) 2000-07-13
JP2013215199A (ja) 2013-10-24
BRPI9913360B8 (pt) 2021-05-25
EP1100880B1 (en) 2010-10-06
WO2000008196A3 (en) 2000-03-30
CA2337967C (en) 2011-11-01
HK1037214A1 (en) 2002-02-01
HUP0103205A2 (hu) 2001-12-28

Similar Documents

Publication Publication Date Title
BR9913360B1 (pt) proteÍna de uricase recombinante quimÉrica, molÉcula de Ácido nuclÉico isolada e purificada, vetor e cÉlula hospedeira transformada.
ATE310090T1 (de) Gereinigte coprinus laccasen und nukleinsäuren welche dafür kodieren
DE60033138D1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
BR9804896A (pt) Dna isolado e purificado, célula hospedeira, vetor, polinucleotídeo quimérico, plasmídeo e processo para aumentar a transcrição de um gene de interesse em uma célula hospedeira
ATE450603T1 (de) Polypeptide mit verzweigungsenzym-aktivität und für diese kodierende nukleinsäuren
AU3217100A (en) Methods of use of a novel lysyl oxidase-related protein
EP1558729A4 (en) QUICKLY REMOVED REPORTER FUSION PROTEINS
EP1847611A3 (en) Rhamnose-inducible expression system
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
AU5727099A (en) A 2,6-beta-d-fructan hydrolase enzyme and processes for using the enzyme
HUP0002234A2 (hu) Amin-oxidáz-aktivitású 1-es vaszkuláris adhéziós fehérje (VAP-1)
WO2002062964A3 (en) Ap1 amine oxidase variants
WO2004087886A3 (en) Modified adenoviral e1a constructs and methods of use thereof
EP0854187A3 (en) Novel glucose 6-phosphate dehydrogenase gene
WO2001016325A3 (en) Plant reproduction proteins
WO2005003289A8 (en) Ap1 amine oxidase variants
WO2002038765A3 (en) Dna encoding bovine immunoglobulin a inducing protein and uses therefor
AU2002234132A1 (en) 13245, a novel human myotonic dystrophy type protein kinase and uses therefor
DE69925927D1 (de) Mutmassliches 98 kd protein des aussenmembrans von chlamydia und dafür kodierende dns sowie deren verwendung
DE69939989D1 (de) Menschliches gas-6 (growth arrest-specific gene 6) Protein und dafür kodierende Nukleinsäuren
WO1999036530A3 (en) Lh-receptor gene promoter for tissue-specific gene expression
ATE430191T1 (de) Überexprimierte und gereinigte aspergillus ficuum oxidase und nukleinsäuren die für sie kodieren
WO2000031269A3 (en) Plant cell proliferation-associated proteins
WO1999053082A3 (en) Hexose carrier proteins
HUP0002349A2 (hu) Citokinin oxidáz enzim és alkalmazásai

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: A REQUERENTE DEVERA SANAR TAL IRREGULARIDADE COMPLETANDO A TAXA RELATIVA A 02 REIVINDICACOES EXCEDENTES.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: O PRESENTE PEDIDO TEVE UM PARECER DE DEFERIMENTO NOTIFICADO NA RPI NO 2188 DE 11/12/2012. UMA VEZ QUE SE CONSTATOU QUE ESTA NOTIFICACAO FOI EFETUADA COM INCORRECAO NO NUMERO DA PETICAO DE DEPOSITO (CITADO NO 0016184200 QUANDO O CORRETO E NO 00161842100), RETIFICA-SE A REFERIDA PUBLICACAO:

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/09/2013, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2473 DE 29-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B24E Patent annual fee: resolution cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.10 NA RPI NO 2494 DE 23/10/2018 POR TER SIDO INDEVIDA.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2473 DE 29/05/2018 POR TER SIDO INDEVIDA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/08/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 05/08/2019